|
Biotechnology is all the RAGE at Athersys. The development-stage company uses its Random Activation of Gene Expression (RAGE) technology to scan the human genome, identify proteins with specific biological functions, and link those protein functions with gene structures (functional genomics). It is also developing therapies for oncology and vascular applications based on its MultiStem technology, which uses stem cells from adult bone marrow. The firm plans to leverage its technologies by partnering with other biotechs and drugmakers, but it also aims to develop its own proprietary drugs. It counts Bristol-Myers Squibb and Angiotech Pharmaceuticals among its partners.
|
| | | Contact Information | |
Address: |
3201 Carnegie Ave.
Cleveland, OH 44115-2634
| | Phone: | 216-431-9900 | | Fax: | 216-361-9495 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2012): | 8.70 M | | Revenue Growth (1 yr): | (-15.80%) | | Employees (2012): | 48 | | Employee Growth (1 yr): | 0.00% |
|
|
Key People
| | • |
Chairman of the Board; Chief Executive Officer:
Gil Bokkelen
| | • |
President, COO, and Secretary:
William (B. J.) Lehmann Jr.
| | • |
VP Finance:
Laura K. Campbell
|
|
|
Industry Information
| |
Sector: | |
Industry: |
|
|
